肿瘤术后转移及复发是导致癌患存活率低的主因。其为复杂多因素调控过程，关键因素包括术前实体瘤招募CD11b+Ly6G+骨髓源系细胞至远端器官构建转移前小生境（PMN），利于循环肿瘤细胞（CTCs）着床定殖；术中CTCs大量入血并逃逸免疫监视；术后复发灶免疫抑制等。同时实现多位点调控是降低术后转移复发的有力手段。本项目构建双载化药和免疫调节剂的苯硼酸-低分子量肝素-生育酚琥珀酸酯（PBA-LMWH-TOS）纳米自传递胶束。亲水段LMWH可抗CD11b+Ly6G+细胞招募，从而抑制PMN重构及削弱肿瘤免疫抑制，阻止血小板黏附CTCs，遏制其免疫逃逸和着床；疏水段TOS可减少CD11b+Ly6G+细胞的MMP-9等促进PMN重构关键因子的表达，协同抗PMN重构；肿瘤释放的相关抗原协同免疫调节剂激活特异性免疫反应，抗击激增的CTCs。该自传递胶束可作用于多个关键环节，多位点遏制肿瘤术后转移及复发。

Postoperative metastasis and recurrence of malignant tumors are the main causes of low survival rate of cancer patients. It is a complex multifactorial process. The key factors include the recruitment of CD11b+Ly6G+ bone marrow-derived cells in distal organs to construct pre-metastatic niches (PMN) before the resection of solid tumors, which facilitates the implantation and colonization of circulating tumor cells (CTCs); a large number of CTCs drop into blood during resection and escape from immune surveillance; and the immunosuppression of recurrent tumors after resection. Therefore, the simultaneously multipoint regulation is a powerful means to reduce the metastasis and recurrence of tumors after resection. In this project, we intend to construct 3-aminophenylboronic acid- low molecular weight heparin- tocopherol succinate (PBA-LMWH-TOS) self-delivering nanomicelles loaded with both chemotherapeutic drug and immunomodulatory drug. The hydrophilic segment LMWH can resist CD11b+Ly6G+ cell recruitment to inhibit PMN remodeling, weaken tumor immunosuppression, prevent platelets from adhering to CTCs, and inhibit the immune escape and implantation of CTCs. The hydrophobic segment TOS can reduce the expression of MMP-9 and other key secretory proteins which promote PMN remodeling in CD11b + Ly6G + cells, and cooperate with anti-PMN remodeling. Tumor-associated antigens released by chemotherapeutic agents killing tumor cells in conjunction with immunomodulators can activate specific immune responses and combat the surge of CTCs. This self-delivering micelle can act on multiple key factors and prevent metastasis and recurrence of tumor after resection.